Apogee Therapeutics, Inc. (NASDAQ:APGE) Insider Carl Dambkowski Sells 4,085 Shares

Apogee Therapeutics, Inc. (NASDAQ:APGE) insider Carl Dambkowski sold 4,085 shares of Apogee Therapeutics stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $46.94, for a total value of $191,749.90. Following the completion of the sale, the insider now directly owns 255,348 shares in the company, valued at $11,986,035.12. This represents a 1.57 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Carl Dambkowski also recently made the following trade(s):

• On Wednesday, December 11th, Carl Dambkowski sold 4,540 shares of Apogee Therapeutics stock. The shares were sold at an average price of $48.76, for a total value of $221,370.40.
• On Wednesday, December 4th, Carl Dambkowski sold 6,665 shares of Apogee Therapeutics stock. The stock was sold at an average price of $46.07, for a total value of $307,056.55.
• On Wednesday, November 6th, Carl Dambkowski sold 6,665 shares of Apogee Therapeutics stock. The stock was sold at an average price of $59.12, for a total transaction of $394,034.80.

Apogee Therapeutics Price Performance

Shares of Apogee Therapeutics stock opened at $47.77 on Friday. Apogee Therapeutics, Inc. has a 1 year low of $27.05 and a 1 year high of $72.29. The business has a 50 day moving average price of $49.13 and a 200 day moving average price of $48.66. The company has a market capitalization of $2.15 billion, a P/E ratio of -19.74 and a beta of 2.30.

Analysts Set New Price Targets

Several analysts recently commented on APGE shares. Wedbush raised their price objective on shares of Apogee Therapeutics from $87.00 to $90.00 and gave the company an “outperform” rating in a research note on Monday, December 2nd. Canaccord Genuity Group began coverage on shares of Apogee Therapeutics in a research report on Monday, November 25th. They set a “buy” rating and a $89.00 price target for the company. Canaccord Genuity Group assumed coverage on Apogee Therapeutics in a report on Monday, November 25th. They issued a “buy” rating and a $89.00 price target on the stock. Finally, Guggenheim reaffirmed a “buy” rating on shares of Apogee Therapeutics in a research note on Thursday, December 12th. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Apogee Therapeutics currently has an average rating of “Buy” and an average target price of $89.71.

Hedge Funds Weigh In On Apogee Therapeutics

Hedge funds have recently bought and sold shares of the stock. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in shares of Apogee Therapeutics during the third quarter valued at $71,000. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Apogee Therapeutics by 21.2% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,628 shares of the company’s stock worth $94,000 after purchasing an additional 285 shares during the last quarter. Allspring Global Investments Holdings LLC purchased a new stake in shares of Apogee Therapeutics during the second quarter worth about $143,000. Wexford Capital LP acquired a new position in shares of Apogee Therapeutics in the third quarter valued at approximately $230,000. Finally, Arizona State Retirement System lifted its stake in shares of Apogee Therapeutics by 4.5% during the second quarter. Arizona State Retirement System now owns 5,993 shares of the company’s stock valued at $236,000 after buying an additional 258 shares during the period. Hedge funds and other institutional investors own 79.04% of the company’s stock.

About Apogee Therapeutics

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.